Velcade-melphalan association as conditioning regimen before autologous stem-cell transplantation in multiple myeloma patients under 65 years.
Phase of Trial: Phase II
Latest Information Update: 15 May 2017
At a glance
- Drugs Bortezomib (Primary) ; Melphalan (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 11 Oct 2011 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
- 11 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Apr 2008 New trial record.